Cytotoxic drugs contract manufacturing market has grown significantly over the last decade. Increasing incidence of cancer and increasing adoption of various growth strategies such as expansion, collaborations, and acquisitions by the key players are expected to boost market growth over the forecast period. Pharmaceutical and biotechnological companies are involved in research and development of cytotoxic drugs and high potency active pharmaceutical ingredients (HPAPIs), and in the manufacture of drugs in-house or outsource the production to other manufacturers.
Market Dynamics
Rising incidence of cancer is expected to propel the market growth over the forecast period. For instance, according to an American Cancer Society estimations, 2017, 1,688,780 people were estimated to be diagnosed with cancer and 600,920 cancer deaths were reported in the U.S.
Increasing product approval for the treatment of cancer is expected to boost growth of the global cytotoxic drugs contract manufacturing market over the forecast period. For instance, in October 2018, Catalent Pharma Solutions received the approval of U.S. Food and Drug Administration (FDA) for Verastem Oncology’s COPIKTRA (duvelisib) capsules.
Furthermore, rising adoption of contract manufacturing services by the pharmaceutical companies is expected to drive growth of the global cytotoxic drugs contract manufacturing market over the forecast period. For instance, in September 2018, GB Sciences, Inc. selected Catalent Pharma Solutions to provide oral delivery systems, formulation development, and clinical-scale oral dose manufacturing of GB Sciences’ proprietary active pharmaceutical ingredients (APIs) for its Parkinson’s disease therapies.
Key features of the study:
- This report provides in-depth analysis of the cytotoxic drugs contract manufacturing market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2019 – 2027), considering 2018 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cytotoxic drugs contract manufacturing market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as part of this study include Lonza Group, Piramal Group, Evonik Industries AG, Novasep Holding SAS, Merck KGaA (SAFC Pharma), Baxter Biopharma Solutions, AbbVie Contract Manufacturing, Cambrex Corporation, BSP Pharmaceuticals S.p.A., CordenPharma International, Catalent, Inc., Albany Molecular Research Inc., Evotec, WuXi AppTec Co., Ltd., Pierre Fabre Laboratories, and Dishman Group
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding their future product launches, technology upgradation, market expansion, and marketing tactics
- The global cytotoxic drugs contract manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the cytotoxic drugs contract manufacturing market
Detailed Segmentation:
- Global Cytotoxic Drugs Contract Manufacturing Market, By Production Scale:
- Industrial scale
- Pilot Scale
- Laboratory Scale
- Global Cytotoxic Drugs Contract Manufacturing Market, By Form:
- Global Cytotoxic Drugs Contract Manufacturing Market, By Product Type:
- Global Cytotoxic Drugs Contract Manufacturing Market, By Region:
- North America
- By Production Scale:
- Industrial scale
- Pilot Scale
- Laboratory Scale
- By Form:
- By Product Type:
- By Country:
- Latin America
- By Production Scale:
- Industrial scale
- Pilot Scale
- Laboratory Scale
- By Form:
- By Product Type:
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Production Scale:
- Industrial scale
- Pilot Scale
- Laboratory Scale
- By Form:
- By Product Type:
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Production Scale:
- Industrial scale
- Pilot Scale
- Laboratory Scale
- By Form:
- By Product Type:
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Production Scale:
- Industrial scale
- Pilot Scale
- Laboratory Scale
- By Form:
- By Product Type:
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Production Scale:
- Industrial scale
- Pilot Scale
- Laboratory Scale
- By Form:
- By Product Type:
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Lonza Group*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Piramal Group
- Evonik Industries AG
- Novasep Holding SAS
- Merck KGaA (SAFC Pharma)
- Baxter Biopharma Solutions
- AbbVie Contract Manufacturing
- Cambrex Corporation
- BSP Pharmaceuticals S.p.A.
- CordenPharma International
- Catalent, Inc.
- Albany Molecular Research Inc. (AMRI)
- Evotec
- WuXi AppTec Co., Ltd.
- Pierre Fabre Laboratories
- Dishman Group
“*” marked represents similar segmentation in other categories in the respective section.
